Bayer HealthCare expands hepatitis testing offering

FDA approval received for automated hepatitis C virus assay on the ADVIA Centaur Immunoassay system

20-Jan-2005

Bayer HealthCare, diagnostics Division, a member of the Bayer Group announced that the U.S. food and Drug Administration (FDA) approved the company's automated assay for the hepatitis C virus (HCV) on its ADVIA Centaur® Immunoassay System. Other FDA-approved, automated hepatitis assays available from Bayer are Anti-HBs and Anti-HBc-IgM.

The HCV assay is developed, manufactured and sold by Bayer Diagnostics for Ortho-Clinical Diagnostics, Inc. (Ortho), a subsidiary of Johnson & Johnson, under an agreement entered into with Bayer, Ortho and Chiron Corporation in 2001. Under the terms of the agreement, Bayer will not represent the product for blood or plasma screening.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures